Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

http://www.wikidata.org/entity/Q39104708

about

Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.Galectin-1 inhibitors and their potential therapeutic applications: a patent review.Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies.Combined temozolomide and ionizing radiation induces galectin-1 and galectin-3 expression in a model of human glioma

P2860

Q26744538-DAF13FBD-5D9C-47A2-AF33-96051D2F3888 Q26991865-9D155977-37DF-498F-8461-4B6A10AB235C Q34438522-69BA6234-4068-4B59-8869-7F88D573B06F Q38763827-3ABF2CDA-2C6C-44DF-9EF5-6D311A188861 Q38764048-298DECA9-E209-42FE-8154-7514C0EA7E28 Q48270428-468559AC-3D7D-4B40-902E-4119128D0646 Q52724033-280214B2-D263-40D4-9F8F-F033130C6988 Q53743967-C86EC182-B541-4825-9B49-6A0249F2148E Q57462651-907AC53D-A06D-455E-8D75-061D0AA4C5A3

P2860

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

http://www.wikidata.org/entity/Q39104708

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Pharmacokinetics and antineopl ...... in combination with sunitinib.

@en

Pharmacokinetics and antineopl ...... in combination with sunitinib.

@nl

type

label

Pharmacokinetics and antineopl ...... in combination with sunitinib.

@en

Pharmacokinetics and antineopl ...... in combination with sunitinib.

@nl

prefLabel

Pharmacokinetics and antineopl ...... in combination with sunitinib.

@en

Pharmacokinetics and antineopl ...... in combination with sunitinib.

@nl

P1433

Q39104708-0DC7C832-92C1-44DE-AAB9-66CB41346E80

P1476

Q39104708-0E357224-67DC-4C34-8CC9-C941360CEADE

P2093

Q39104708-5498DB5F-9C01-4349-8CC1-33B52A2E05C3

Q39104708-AD8E9AE9-F7CD-436C-ACCD-C291809EE575

Q39104708-CEAB76E7-2457-4669-8B8A-BECF80DD37C8

Q39104708-DFF46EA9-7A73-4669-84FA-C71D9FD8BB49

Q39104708-E49F0DD9-B11B-4941-BDC0-40D66A77819A

Q39104708-E64B53C1-74B9-481B-AD56-17DDE1284668

P2860

Q39104708-1A32EC79-F5A3-40EC-9518-5D075A545B4D

Q39104708-348BC8B2-EFFA-4C35-9018-58F18BFA3C03

Q39104708-3DDE1ACE-79EB-4D26-981D-764AA1C0CB43

Q39104708-40D72033-DE6A-4A2A-A98C-F9B089059ED0

Q39104708-454B0E4C-BA1E-4526-A3A8-E1A675247F56

Q39104708-634614CE-7EB7-496A-80EB-99CF56F043EA

Q39104708-652CA958-B145-4D26-B69D-10C28D2D7446

Q39104708-78003C57-7D7E-4C77-A299-A9F1A9897A55

Q39104708-7A760787-ED1D-49EB-8DD3-D7EEBE29CE29

Q39104708-8F5382CD-66CB-4A03-BE8B-A8A1AE5D0C93

P2888

Q39104708-498BDFDB-9A9B-48C2-AD06-38FBE6DCBAE6

P304

Q39104708-94B8B5E6-36D1-4E57-8F46-E9D3920E2758

P31

Q39104708-E5108B0C-B5F8-4E94-B179-F042656F1DA6

P356

Q39104708-033B39D3-8933-411F-983C-42BF53579AD8

P433

Q39104708-3F07F31A-11F7-48A5-889C-6F4F7C2BE6F5

P478

Q39104708-E63E153E-6EB4-4FCA-8BBC-193F1B281D9E

P50

Q39104708-1C2BB03B-FD2B-48F9-ADA4-4D1C3EAAE897

Q39104708-4AC06B99-2964-48E3-9C12-71227F9DBBA6

Q39104708-642123A9-39F8-4532-AA76-277EFC2E28EE

Q39104708-A3D731E2-39D6-4C00-B49F-FDE9B98B8D32

Q39104708-C38CD366-0C85-42DE-92A4-189D84CF7E74

Q39104708-D40B9E45-E2B2-46E8-B02B-EE093C43D161

P577

Q39104708-89CCAB04-5725-411D-B516-DE5E9944FD3F

P698

Q39104708-4A8C8A91-3CE7-427F-A5A0-7AB668E73236

P356

S00280-013-2270-2

P1433

Cancer Chemotherapy and Pharmacology

P1476

Pharmacokinetics and antineopl ...... in combination with sunitinib

@en

P2093

Esteban Cvitkovic

http://www.w3.org/2001/XMLSchema#string

Federica Sala

http://www.w3.org/2001/XMLSchema#string

Katiuscia Bonezzi

http://www.w3.org/2001/XMLSchema#string

Kay Noel

http://www.w3.org/2001/XMLSchema#string

Monique Zangarini

http://www.w3.org/2001/XMLSchema#string

Patrizia Borsotti

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Molecular mechanisms and clinical applications of angiogenesis

Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities.

Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

Galectins as modulators of tumour progression.

Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding

Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.

The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins.

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

Galectin-1 as a potential cancer target.

P2888

s00280-013-2270-2

P304

879-887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2270-2

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Raffaella Giavazzi

Massimo Zucchetti

Maurizio D'Incalci

Giulia Taraboletti

P577

2013-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23978989

http://www.w3.org/2001/XMLSchema#string